ERBITUX® is an epidermal growth factor receptor (EGFR) antagonist indicated for treatment of:...Colorectal Cancer: K-Ras wild-type, EGFR-expressing, metastatic colorectal cancer as determined by an FDA-approved test...in combination with FOLFIRI for first-line treatment…in combination with irinotecan in patients who are refractory to irinotecan-based chemotherapy… as a single-agent in patients who have failed oxaliplatin- and irinotecan-based chemotherapy or who are intolerant to irinotecan.

All patients were high-grade histological types, and EGFR expression was positive in all examined patients... Our study revealed a preferable objective response rate of Cmab-PTX for patients with high-grade SGC. Although the treatment sensitivity of SGC with high-grade histological types is usually poor, Cmab-PTX could be a promising treatment regimen for recurrent SGC.